RTI Surgical Transforms into Evergen, Focuses on Regenerative Medicine

• RTI Surgical has rebranded as Evergen, reflecting its strategic evolution into a premier CDMO in regenerative medicine.

• The transformation follows acquisitions of Cook Biotech and Collagen Solutions, creating a unique portfolio of biomaterials.

RTI Surgical, a CDMO in tissue engineering and regenerative medicine, has announced its rebranding as Evergen. This marks the company’s evolution into a top-tier Contract Development and Manufacturing Organization (CDMO) focused on innovative biosolutions.

The rebranding follows a pivotal year, highlighted by the acquisitions of Cook Biotech and Collagen Solutions. These integrations position Evergen as the only CDMO capable of delivering both allograft and xenograft biomaterials at scale.

Olivier Visa, President and CEO, commented, “As Evergen, we are positioned to lead a new era of regenerative medicine by becoming the trusted CDMO of choice for OEM partners.”

Evergen’s solutions will cater to therapeutic areas such as cardiac, sports medicine, orthopaedic surgery, and more. The move reinforces its commitment to advancing patient-centred innovations while strengthening internal cohesion. Chief People Officer Kim Spooner noted, “Our new brand identity honours our rich heritage and unifies our employees as we become one team.”